Table 1.
Change over time in the 2p+ clone after various treatments
| Treatment | Prior lines of treatment | 2p+ before treatment | CK (>3) before treatment | del(17p) before treatment | TP53 mutd before treatment | del(11q) before treatment | Un‐IGHV | Time to next 2p+ evaluation | Disease status when the second sample was collected | Decrease in 2p+ | Stable 2p+ | Increase in 2p+ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients not treated when 2p+ was first detected | ||||||||||||
| FCR n = 5 | 0 | 5/5 | 1/3 | 0/5 | 0/3 | 3/5 | 4/4 | Median (range): 45 m (32 m‐59 m) | relapse | 0 | 3 | 2 |
| BR n = 1 | 0 | 1/1 | 1/1 | 0/1 | 0/1 | 1/1 | na | 26 m | relapse | 0 | 1 | 0 |
| Patients already treated when 2p+ was first detected | ||||||||||||
| FCR n = 2 | 0‐1 | 1/2 | 0/1 | 0/2 | 0/1 | 1/2 | 0/1 | 26 m‐29 m | relapse | 0 | 1 | 1a |
| BR n = 2 | 1 | 2/2 | 1/2 | 0/2 | 0/2 | 2/2 | 1/1 | 3 m‐7 m | remission | 2 | 0 | 0 |
| BOMP n = 11 | 1‐3 | 10/11 | 4/10 | 5/11 | 5/11 | 8/11 | 11/11 | Median (range): 14 m (5 m‐62 m) | relapse | 4b | 4 | 3c |
| Ibrutinib n = 5 | 1‐6 | 5/5 | 3/5 | 3/5 | 2/3 | 1/5 | 3/4 | Median (range): 11 m (5 m‐20 m) | normal/decreased lymphocytosis (n = 4)/relapse (n = 1) | 2 | 3 | 0 |
| Idelalisib + R n = 2 | 2 | 2/2 | 2/2 | 2/2 | na | 0/2 | 2/2 | 13‐16 m | partial remission (n = 1)/relapse (n = 1) | 0 | 2 | 0 |
CK: complex karyotype > 3 chromosomal abnormalities; na: not available; Un, unmutated.
a
The 2p gain appeared after FCR treatment (CLL_1).
b
In one case (CLL_43), the 2p gain was no longer detected.
c
In one case (CLL_5), the 2p gain appeared after BOMP treatment.
d
No cases with a TP53 mutation (mut) but no del(17p).